RenovoRx, Inc. · NASDAQ:RNXT
RenovoRx — SIR 2024
13 slides from RenovoRx's conference presentation, Mar 17, 2024
Slide 1: Mesenteric Venous Thrombosis as a Predictor of Target Artery Thrombosis and TAMP Completion
Mesenteric Venous Thrombosis as a Predictor of Target Artery Thrombosis and Trans-Arterial Micro Perfusion Treatment Completion Among Patients with Locally Advanced Pancreatic Cancer Dr. David Sperling1, Dr. Justin Lee2, Dr. Sandeep Laroia3, Dr. Paula Novelli4, George Andary5, Dr. Ramtin Agah5, Dr.
Slide 2: Chemotherapy is Not Effectively Delivered to Primary Pancreatic Tumors
Chemotherapy is Not Effectively Delivered to Primary Pancreatic Tumors Dense fibrotic stroma | Sparse tumor cellularity | Hypovascular tumors Liver tumors are vascularized Pancreas tumors are hypovascular • Large tumor feeders – excellent targets for therapy • Inability to identify tumor feeder vess
Slide 3: Trans-Arterial Micro-Perfusion (TAMP): Method of Intra-arterial Delivery of Chemotherapy
Trans-Arterial Micro-Perfusion (TAMP): Method of Intra-arterial Delivery of Chemotherapy Independent of Feeder Vessels Mechanism: after vessel isolation, increase in Increases Drug Concentration to Target Pathological Site by ~100X* pressure forces drug across the artery wall Compared to IV Administ
Slide 4: Phase III TIGeR-PaC Study design
Phase III TIGeR-PaC Study: Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer INDUCTION PHASE 1:1 RANDOMIZATION PHASE 4-Months of Treatment with: Continuation IV Gemcitabine + Nab-Pac (SOC) vs IA Gemci
Slide 5: TIGeR-PaC: Tolerability and Safety of Treatment
TIGeR-PaC: Tolerability and Safety of Treatment Tolerability during active treatment: • 61% of IA patients received all planned treatments at the pre-specified dose vs. 18% of IV (primarily due to AEs or SAEs) • Patients receiving IA therapy had more nausea and abdominal pain events • Patients recei
Slide 6: TIGeR-PaC Primary Endpoint: Overall Survival
TIGeR-PaC Primary Endpoint: Overall Survival IV Gemcitabine IA Gemcitabine + Nab-Pac IA Gemcitabine Patients n = 23 n = 22 Median OS, months SURVIVING PROBABILITY 15.7 10.1 (95% CI) HR (95% CI) 0.48 (0.2-1.12) IV Gemcitabine + P value p<0.08 Nab-Paclitaxel Censored # of Subjects at Risk STUDY MONTH
Slide 7: Limitation for Repeat Procedure: Arterial Thrombosis
Limitation for Repeat Procedure: Arterial Thrombosis • At first interim analysis, 61% of TIGeR-PaC IA patients received all planned treatments at the pre-specified dose • Of the 39% that did not receive all planned procedures, the major reason was arterial thrombosis during attempt for repeat proced
Slide 8: Thrombosis in Pancreatic Cancer
Thrombosis in Pancreatic Cancer Arterial Thromboembolism in Cancer Patients Treated with Apixaban • Patients are at risk of both arterial (ATE) and venous thrombo-embolism (VTE), although the incidence of VTE is higher than ATE • PDAC carries the highest risk of VTE among all cancers, with rates of
Slide 9: Can Risk of Arterial Thrombosis in TAMP be Predicted?
Can Risk of Arterial Thrombosis in TAMP be Predicted? Key Questions: • Is arterial thrombosis in TAMP patients related to increased hypercoagulable state? Or does it occur independently of patient predisposition for thrombosis, indicating a direct relationship to the TAMP procedure? • Mesenteric vei
Slide 10: Relationship of Baseline MVT to Arterial Thrombosis with TAMP: Methods
Relationship of Baseline MVT to Arterial Thrombosis with TAMP: METHODS • Utilizing the TIGeR-PaC analysis results, we compared the incidence of arterial thrombosis in consecutive TAMP-randomized study participants with vs. without baseline MVT • The presence or absence of MVT on baseline CT was dete
Slide 11: Relationship of Baseline MVT to Arterial Thrombosis with TAMP: Results
Relationship of Baseline MVT to Arterial Thrombosis with TAMP: RESULTS • Of the 25 subjects randomized to TAMP therapy, 11 failed to complete 8 cycles of treatment. • Of these 11 patients, 6 failed completion due to thrombosis of the targeted arterial artery (24% of total cohort) • Among those 6 sub
Slide 12: Conclusions
Conclusions • TAMP is a novel technique for localized chemotherapeutic delivery with promising early clinical data for both survival and decreased side effects compared to conventional chemotherapy in patients with PDAC (TIGeR-PaC interim analysis results) • The major limitation of TAMP for repeated
Slide 13: Extra Slide
Extra Slide Ss | R= 2024 mren er SIRpass the summit